Member Info for PM44

Results but not much more or less than our best researchers already knew but it's encouraging to hear it straight from the horse's mouth.
Just what we needed in these depressing times: reassurance that the best is yet to come, it's only question of time, again! One day soon......it will!

Morning Cleaner and welcome,
I too invest in both companies and just added to Ceres yesterday after the sharp drop, risky but hope it will pay in the long run.
It's possible that the oil thing has been orchestrated, but in the long ran cannot be manipulated indefinitely, the market is gradually moving to electric/hydrogen because the demand is taking traction and the technology is improving at a fast pace now. I invest here because I believe in its future and ignore the noise around.

Thanks Piller,
Next Monday interim results on top of that, so jittery time till then.

On this b.b. considering the s.p. is down over double the average market drop.
Anybody know of any particular reason for this? Thanks!

Many thanks!

I know there are plenty of good reserchers on this b.b. , but PLEASE don't reply all at once !!! :)))

In the motoring section, mentions an Audi prototype called Amy (AI:ME), which can read your mind by tracking the movements of your eyes even through sunglasses when you're looking at a 55inc dashboard display. Our tech???

I assumed likely volatility between now and recovery would mean even more trades. Both scenarios are possible?

Waiting.

That this stockbroker share price is down, considering that is making money on a massive amount of trades and will do it again when the markets recover!

Yes very good post RM,
In a strange way, by making it sound more difficult, it gives the confidence of staying with it!
It's so good and reassuring that it deserves a tick up on Monday!

Not a good position to be over reliant on China at the moment.
Would SEYE investors start to switch to us as soon as we get a good RNS? Whenever that will be!

Hoops!
Sorry about the repeat prescription (just in case you missed the first one! :) )

Yes, another encouraging endorsement!
UHB's choice of Advanced Oncotherapy not only strengthens our leading position as technology disruptor in proton therapy, but also demonstrates our strong momentum and the clear opportunity we have to meet a significant unmet medical need: only 200 treatment rooms today globally but a need of at least 10,000 treatment rooms if only 20% of patients undergoing radiotherapy are treated with proton therapy.

 

With three partnerships announced in the last two months - the Cleveland Clinic, The London Clinicand the Mediterranean Hospital of Limassol - this fourth agreement is another important step for us as a Company and it is in line with our continuous commitment to defeat cancer."

 Yes another encouraging endorsement!

UHB's choice of Advanced Oncotherapy not only strengthens our leading position as technology disruptor in proton therapy, but also demonstrates our strong momentum and the clear opportunity we have to meet a significant unmet medical need: only 200 treatment rooms today globally but a need of at least 10,000 treatment rooms if only 20% of patients undergoing radiotherapy are treated with proton therapy.

 

With three partnerships announced in the last two months - the Cleveland Clinic, The London Clinicand the Mediterranean Hospital of Limassol - this fourth agreement is another important step for us as a Company and it is in line with our continuous commitment to defeat cancer."

 UHB's choice of Advanced Oncotherapy not only strengthens our leading position as technology disruptor in proton therapy, but also demonstrates our strong momentum and the clear opportunity we have to meet a significant unmet medical need: only 200 treatment rooms today globally but a need of at least 10,000 treatment rooms if only 20% of patients undergoing radiotherapy are treated with proton therapy.

 

With three partnerships announced in the last two months - the Cleveland Clinic, The London Clinicand the Mediterranean Hospital of Limassol - this fourth agreement is another important step for us as a Company and it is in line with our continuous commitment to defeat cancer."

 
UHB's choice of Advanced Oncotherapy not only strengthens our leading position as technology disruptor in proton therapy, but also demonstrates our strong momentum and the clear opportunity we have to meet a significant unmet medical need: only 200 treatment rooms today globally but a need of at least 10,000 treatment rooms if only 20% of patients undergoing radiotherapy are treated with proton therapy.



With three partnerships announced in the last two months - the Cleveland Clinic, The London Clinic and the Mediterranean Hospital of Limassol - this fourth agreement is another important step for us as a Company and it is in line with our continuous commitment to defeat cancer."

Of course this IS good news, it's also refreshing that there been transparency regarding the sale being subject to regulatory approval. What I find important is the confidence and belief of new customers in our product, enough to start committing to orders, while of course protecting themselves, just in case. Another encouraging step in the right direction! Let's get approval done!!!

If Steven Smith is Candy and added 100000 on the 11th of February,
where the extra 100000 come from after the previous purchase of 25000 on the 2nd Sep 2019???

Of course you are correct, Zoff.

Maybe I am missing something but where do you read that there will be Two treatment rooms?
London clinic is saying that the treatment room will be next to them, which I understand is the AVO premises and London clinic will run it instead of Circle, please explain your reasons for saying two ?

This is not the way I understand it, it sounds to me that the London clinic will ran our Harley street premises instead of Circle and AVO will provide the equipment. Circle agreement has lapsed I assume because of delays. Even this new agreement is only an mou and no details are available! Not pleased!

If the demand is high, it would take decades for direct manufacturing to match supply and demand.